Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

Inclusion criteria: Healthy subjects: \- Men and women ≥18 and ≤55 years of age with a body mass index (BMI) ≥18 and ≤32 kg/m2 (non-Japanese subjects) and ≥18 and ≤28 kg/m2 (Japanese subjects) Patients with Parkinson's disease: * Men and women with a clinical diagnosis of idiopathic Parkinson's disease, Hoehn and Yahn (H\&Y, stage 1-3) * For a minimum of three months prior to enrolment, Parkinson's disease symptoms have been stable and is anticipated to be stable during the study duration as judged by the PI * If on Parkinson's disease treatment the dose must be stable for a minimum of three months prior to enrolment and is anticipated to be stable during the study duration as judged by the PI * ≥40 and ≤80 years of age * BMI ≥18 and ≤35 kg/m2 Exclusion criteria: * Atypical Parkinsonism * Clinically relevant structural brain abnormality, as assessed using MRI * Mild cognitive impairment, measured as a Montreal cognitive assessment (MoCA) score =\<21 * Any past or current treatment with an active vaccine targeting alpha-synuclein * Any past or current treatment with a monoclonal antibody within the last 12 months Other in- and exclusion criteria may apply.